{"nctId":"NCT00193596","briefTitle":"Gemcitabine/Irinotecan/ZD1839 vs Paclitaxel/Carboplatin/Etoposide/ZD1839 in Carcinoma of Unknown Primary Site","startDateStruct":{"date":"2003-09"},"conditions":["Neoplasms, Unknown Primary"],"count":198,"armGroups":[{"label":"Regimen A","type":"EXPERIMENTAL","interventionNames":["Drug: Etoposide","Drug: Paclitaxel","Drug: Carboplatin"]},{"label":"Regimen B","type":"EXPERIMENTAL","interventionNames":["Drug: Gemcitabine","Drug: Irinotecan"]}],"interventions":[{"name":"Etoposide","otherNames":["Etopophos","Toposar"]},{"name":"Gemcitabine","otherNames":["Gemzar"]},{"name":"Irinotecan","otherNames":["Camptosar"]},{"name":"Paclitaxel","otherNames":["Abraxane"]},{"name":"Carboplatin","otherNames":["Paraplatin"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\nTo be included in this study, you must meet the following criteria:\n\n* Carcinoma of unknown primary site\n* Biopsy-proven metastatic carcinoma\n* Able to perform activities of daily living with minimal assistance\n* No previous treatment with any systemic therapy\n* Measurable or evaluable disease\n* Adequate bone marrow, liver and kidney function\n* Understand the nature of this study and give written informed consent\n\nExclusion Criteria:\n\nYou cannot participate in this study if any of the following apply to you:\n\n* Age \\< 18 years\n* Uncontrolled brain metastases and meningeal involvement\n* Other uncontrolled malignancies\n* Women pregnant or lactating\n* Recent history of significant cardiovascular disease\n* Severe or uncontrolled systemic disease\n* Other significant clinical disorder\n* Clinically active interstitial lung disease\n\nPlease note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Overall Survival (OS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Death","description":"Length of time, in months, that patients were alive from their first date of protocol treatment until death.","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.4","spread":null},{"groupId":"OG001","value":"8.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Progression Free Survival (PFS), the Length of Time, in Months, That Patients Were Alive From Their First Date of Protocol Treatment Until Worsening of Their Disease","description":"Length of time, in months, that patients were alive from their first date of protocol treatment until worsening of their disease","paramType":"MEDIAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"5.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":56,"n":93},"commonTop":["Fatigue","Nausea","Pain","Anorexia","Hemoglobin"]}}}